Health Care [ 6/12 ] | Biotechnology [ 27/74 ]
NASDAQ | Common Stock
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.
Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression.
The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders.
The company was founded in 2018 and is based in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 27, 25 | -0.17 Increased by +19.05% | -0.22 Increased by +24.11% |
| Nov 14, 24 | -0.23 Decreased by -109.09% | -0.25 Increased by +8.91% |
| Sep 3, 24 | -0.20 Decreased by -33.33% | -0.22 Increased by +9.09% |
| May 3, 24 | -0.15 Increased by +28.57% | -0.22 Increased by +31.82% |
| Feb 29, 24 | -0.21 Increased by +34.38% | -0.20 Decreased by -5.00% |
| Nov 9, 23 | -0.11 Decreased by -1.00 K% | -0.20 Increased by +45.00% |
| Aug 23, 23 | -0.15 Decreased by -1.60 K% | -0.25 Increased by +40.00% |
| May 11, 23 | -0.21 Decreased by -90.91% | -0.22 Increased by +4.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -8.80 M Increased by +21.91% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -12.11 M Decreased by -114.45% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -10.38 M Decreased by -34.29% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 80.00 K Increased by +N/A% | -7.67 M Increased by +36.69% | Decreased by -9.58 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -11.27 M Increased by +32.95% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.65 M Decreased by -198.35% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.73 M Decreased by -204.19% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.11 M Decreased by -244.01% | Decreased by N/A% Decreased by N/A% |